Document Detail

Comparing the effects of white coat hypertension and sustained hypertension on mortality in a UK primary care setting.
MedLine Citation:
PMID:  18779542     Owner:  NLM     Status:  MEDLINE    
PURPOSE: We examined all-cause mortality within a primary care setting in patients with white coat hypertension or sustained hypertension in whom blood pressure (BP) monitoring was indicated.
METHODS: This prospective multicenter study of ambulatory BP monitoring included 48 family practices in the county of Oxfordshire, United Kingdom. Mortality was compared for patients having white coat hypertension (mean of 3 clinic BP readings >140/90 mm Hg and daytime ambulatory readings< or =135/85 mm Hg) and patients having sustained hypertension (mean of 3 clinic readings >140/90 mm Hg and daytime ambulatory readings >135/85 mm Hg).
RESULTS: A routine primary care cohort consisting of 5,182 patients chosen to undergo ambulatory BP monitoring by their family physician was followed up for a median of 7.3 years (interquartile range, 5.8-8.9). There were 335 deaths (6.5%), corresponding to a mortality rate of 8.9 deaths (95% confidence interval [CI], 8.0-9.9) per 1,000 years of follow-up. Patients with white coat hypertension (n = 1,117) were more likely to be female and were on average younger than patients with sustained hypertension (n = 4,065). The unadjusted rate of all-cause mortality in patients with white coat hypertension was lower, at 4.4 deaths per 1,000 years of follow-up (95% CI, 3.1-6.0) than that in patients with sustained hypertension, at 10.2 deaths per 1,000 years of follow-up (95% CI, 9.1-11.4). This reduction in all-cause mortality was still clinically significant after adjustment for age, sex, smoking, use of antihypertensive medication, and practice-clustering effects (hazard ratio = 0.64; 95% CI, 0.42-0.97; P=.04).
CONCLUSIONS: White coat hypertension (elevation of clinic BP only) confers significantly less risk of death than sustained hypertension (elevation of both clinic and ambulatory BPs). Trials are now needed to evaluate the risk reduction achievable in patients who have white coat hypertension and are receiving BP-lowering therapy.
Martin G Dawes; Gillian Bartlett; Andrew J Coats; Edmund Juszczak
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of family medicine     Volume:  6     ISSN:  1544-1717     ISO Abbreviation:  Ann Fam Med     Publication Date:    2008 Sep-Oct
Date Detail:
Created Date:  2008-09-09     Completed Date:  2008-12-10     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  101167762     Medline TA:  Ann Fam Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  390-6     Citation Subset:  IM    
Department of Family Medicine, McGill University, Montreal, Quebec, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Distribution
Antihypertensive Agents / adverse effects,  therapeutic use
Blood Pressure Monitoring, Ambulatory
Great Britain / epidemiology
Hypertension / drug therapy,  epidemiology,  mortality*,  psychology
Middle Aged
Primary Health Care / statistics & numerical data*
Prospective Studies
Risk Assessment
Sex Distribution
Smoking / adverse effects,  epidemiology
Reg. No./Substance:
0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomi...
Next Document:  Impact of Title VII training programs on community health center staffing and national health servic...